Halozyme Therapeutics, Inc.· HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

• 

  4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026

  Four GARP stocks combine discounted PEG ratios with strong growth prospects, offering investors value and potential in 2026.

  Sep 4, 2026
• 

  Halozyme to Participate at Upcoming Investor Conferences

  SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.

  Sep 2, 2026
• 

  Halozyme: The Market May Be Underpricing The Second Growth Wave

  Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.

  Sep 1, 2026
• 

  Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

  Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

  Aug 31, 2026
• 

  Canada Pension Plan Investment Board Purchases Shares of 132,600 Halozyme Therapeutics, Inc. $HALO

  Canada Pension Plan Investment Board acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,600 shares of the biopharmaceutical company's stock, valued at approximately $10,379,000. Canada Pension Plan Investment

  Aug 30, 2026

• MS

  Halozyme price target raised to $105 from $93 at Morgan Stanley

  Morgan Stanley· Sean Laaman· $105.00
  Aug 7, 2026
• HW

  Halozyme price target raised to $95 from $90 at H.C. Wainwright

  H.C. Wainwright· Mitchell Kapoor· $95.00
  Apr 29, 2026
• GS

  Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'

  Goldman Sachs· Corinne Jenkins· $56.00
  Dec 4, 2025